To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06441747
Title Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Chris O'Brien Lifehouse NOT_YET_RECRUITING Camperdown New South Wales 2050 Australia Details
Monash Medical Centre NOT_YET_RECRUITING Clayton New South Wales 3168 Australia Details
Westmead Hospital NOT_YET_RECRUITING Westmead New South Wales 2145 Australia Details
Wollongong Hospital NOT_YET_RECRUITING Wollongong New South Wales 2500 Australia Details
Royal Brisbane Women's Hospital NOT_YET_RECRUITING Brisbane Queensland 4006 Australia Details
Princess Alexandra Hospital NOT_YET_RECRUITING Woolloongabba Queensland 4102 Australia Details
Flinders Medical Centre NOT_YET_RECRUITING Bedford Park South Australia Australia Details
Austin Health RECRUITING Melbourne Victoria 3084 Australia Details
Western Health NOT_YET_RECRUITING Saint Albans Victoria 3021 Australia Details
St John of God Hospital, Subiaco NOT_YET_RECRUITING Perth Western Australia Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field